Theravance Biopharma R&d Ip, LLC

Diana Jin Wang

Robert Murray McKinnell

Erik Fenster

Tom M Lam

Breena Gloriana Fraga

Anthony Francesco Palermo

Miroslav Rapta

Venkat R Thalladi

Jerry Nzerem

Marta Dabros

Mandy Loo

Luke Boralsky

The disclosure provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The disclosure also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal inflammatory diseases.

Fused pyrimidine pyridinone compounds as JAK inhibitors

The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.

Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

Growing community of inventors

Dublin, CA, United States of America

Diana Jin Wang